TY - JOUR
T1 - Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction
AU - Hoekstra, Tialda
AU - Lesman-Leegte, Ivonne
AU - van Veldhuisen, Dirk J.
AU - Sanderman, Robbert
AU - Jaarsma, Tiny
PY - 2011/9
Y1 - 2011/9
N2 - Aims To compare quality of life (QoL) in heart failure (HF) patients with preserved ejection fraction (HF-PEF) and HF patients with reduced ejection fraction (HF-REF) in a well-defined HF population.Methods and results Patients with HF-PEF [left ventricular ejection fraction (LVEF) >= 40%] were matched by age and gender to patients with HF-REF (LVEF,40%). In the current study, we only included HF patients with a B-type natriuretic peptide level (BNP) > 100 pg/mL. Quality of life was assessed by Cantril's Ladder of Life, RAND-36, and the Minnesota Living with Heart Failure questionnaire, and impairment of QoL was adjusted for by BNP as a marker for severity of HF. We examined a total of 290 HF patients, of whom 145 had HF-PEF (41% female; age 72 +/- 10; LVEF 51 +/- 8%) and 145 had HF-REF (41% female; age 73 +/- 10, LVEF 26 +/- 7%). All HF patients reported markedly low scores of QoL, both on the general and disease-specific QoL questionnaires. Quality of life between patients with HF-PEF and HF-REF did not differ significantly. When adjusting the QoL scores for BNP, an association between QoL and LVEF was not found, i.e. patients with HF-PEF and HF-REF with similar BNP levels had the same impairment in QoL.Conclusion Quality of life is similarly impaired in patients with HF-PEF as in HF-REF. These findings further support the need for more pharmacological and non-pharmacological studies in patients with HF-PEF.
AB - Aims To compare quality of life (QoL) in heart failure (HF) patients with preserved ejection fraction (HF-PEF) and HF patients with reduced ejection fraction (HF-REF) in a well-defined HF population.Methods and results Patients with HF-PEF [left ventricular ejection fraction (LVEF) >= 40%] were matched by age and gender to patients with HF-REF (LVEF,40%). In the current study, we only included HF patients with a B-type natriuretic peptide level (BNP) > 100 pg/mL. Quality of life was assessed by Cantril's Ladder of Life, RAND-36, and the Minnesota Living with Heart Failure questionnaire, and impairment of QoL was adjusted for by BNP as a marker for severity of HF. We examined a total of 290 HF patients, of whom 145 had HF-PEF (41% female; age 72 +/- 10; LVEF 51 +/- 8%) and 145 had HF-REF (41% female; age 73 +/- 10, LVEF 26 +/- 7%). All HF patients reported markedly low scores of QoL, both on the general and disease-specific QoL questionnaires. Quality of life between patients with HF-PEF and HF-REF did not differ significantly. When adjusting the QoL scores for BNP, an association between QoL and LVEF was not found, i.e. patients with HF-PEF and HF-REF with similar BNP levels had the same impairment in QoL.Conclusion Quality of life is similarly impaired in patients with HF-PEF as in HF-REF. These findings further support the need for more pharmacological and non-pharmacological studies in patients with HF-PEF.
KW - Heart failure
KW - Quality of life
KW - Preserved ejection fraction
KW - Reduced ejection fraction
KW - B-type Natriuretic Peptide
KW - EUROPEAN-SOCIETY
KW - DOUBLE-BLIND
KW - MORTALITY
KW - ASSOCIATION
KW - PREDICTOR
KW - BLOCKADE
KW - OUTCOMES
KW - DESIGN
KW - PEOPLE
KW - CHARM
U2 - 10.1093/eurjhf/hfr072
DO - 10.1093/eurjhf/hfr072
M3 - Article
SN - 1388-9842
VL - 13
SP - 1013
EP - 1018
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 9
ER -